COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
COMPASS Pathways Trading Down 5.4%
Shares of NASDAQ:CMPS traded down $0.25 during midday trading on Thursday, reaching $4.37. The company's stock had a trading volume of 1,305,244 shares, compared to its average volume of 2,617,600. The firm has a market capitalization of $408.86 million, a price-to-earnings ratio of -2.20 and a beta of 2.12. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.18 and a current ratio of 10.18. The firm has a 50 day moving average price of $4.00 and a two-hundred day moving average price of $3.78. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.54.
Hedge Funds Weigh In On COMPASS Pathways
An institutional investor recently raised its position in COMPASS Pathways stock. Royal Bank of Canada boosted its position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 49.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 89,446 shares of the company's stock after purchasing an additional 29,733 shares during the period. Royal Bank of Canada owned about 0.10% of COMPASS Pathways worth $256,000 as of its most recent SEC filing. Institutional investors and hedge funds own 46.19% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, July 15th. Evercore ISI reaffirmed an "in-line" rating and set a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $12.00 price objective on shares of COMPASS Pathways in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.
Check Out Our Latest Stock Report on CMPS
COMPASS Pathways Company Profile
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Read More
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
